What is Sino Biological,Inc.'s (301047.SZ) StockRank?

MoatMap's StockRank for Sino Biological,Inc. (301047.SZ) is 70/100, with a Buy signal. This is a composite score combining Quality (63), Value (40), and Momentum (54) factor ranks across MoatMap's 19,000+ stock universe.

Does Sino Biological,Inc. have an economic moat?

Sino Biological,Inc. (301047.SZ) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Sino Biological,Inc. a buy, hold, or sell?

MoatMap's current signal for Sino Biological,Inc. (301047.SZ) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Sino Biological,Inc. in?

Sino Biological,Inc. (301047.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301047.SZ

BUYFLAG

Sino Biological,Inc. · Healthcare · China · $1.1B · Avg Vol: $8M/d

StockRank

P/E (TTM)

46.7x

ROE

2.8%

D/E

0.0x

Dividend %

8.6%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Sino Biological is a high-quality provider of recombinant proteins and contract research services, positioning it well for the CDMO pricing power cycle. However, geopolitical tensions and domestic biotech funding constraints in China present near-term headwinds that offset its strong balance sheet and high-margin product portfolio.

COMPANY DESCRIPTION

Sino Biological is a global provider of recombinant proteins, antibodies, and related research reagents for life science research and drug development. The company possesses one of the world's largest independent collections of recombinant proteins, serving as a critical supplier to global biopharmaceutical firms and academic institutions. It is a highly profitable, research-driven niche leader with a strong international sales footprint.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	85M	96M	91M	103M	6.8%
EPS	0.39	0.30	0.14	0.18	-23.0%
Shares	129M	129M	122M	122M	-5.9%
Debt	10M	13M	10M	8M	-8.8%
Equity	941M	941M	853M	785M	-5.9%
Op CF	37M	48M	17M	22M	-16.3%
Inv CF	-9M	-176M	-64M	64M	—
Fin CF	-104M	-43M	-109M	-94M	—

PRICE (1M)-13.8%

SMA 50SMA 200

$8.90

RSI (14)

31.1

52W High

$12.35

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

3.4%52.0

ROE

2.8%50.4

GP/Assets

9.6%25.1

Op. Margin

17.5%78.6

FCF/Assets

-0.7%48.5

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.01x89.2

Current Ratio

26.66x97.3

Value

P/E (TTM)

46.7x22.1

EV/EBITDA

23.5x15.3

P/FCF

—N/A

P/B

1.4x69.4

P/S

10.1x26.0

Div Yield

8.6%98.4

Momentum

52W High %

72%59.4

RS 6M

-18%57.8

SMA 50/200

0.97x53.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

42%73.4

FUNDAMENTALS

Market Cap

$1.1B

P/E (Forward)

—

Gross Margin

73.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301047.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301047.SZ	Sino Biological,Inc.(you)	$1.1B	70	BUY
688046.SS	GemPharmatech Co., Ltd.	$1.2B	70	BUY
688105.SS	Nanjing Vazyme Biotech Co., Ltd	$1.1B	63	HOLD
300841.SZ	Chengdu Kanghua Biological Products Co., Ltd.	$917M	67	BUY
688253.SS	Innovita Biological Technology Co., Ltd.	$1.1B	58	HOLD
000990.SZ	Chengzhi Co., Ltd.	$1.7B	63	HOLD
688315.SS	Novogene Co., Ltd.	$870M	60	HOLD
605116.SS	Aurisco Pharmaceutical Co.,Ltd.	$1.2B	56	HOLD
688526.SS	Wuhan Keqian Biology Co.,Ltd	$906M	83	STRONG BUY
688202.SS	Shanghai Medicilon Inc.	$1.2B	53	HOLD

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Sino Biological,Inc. (301047.SZ) — Stock Score Summary

Sino Biological,Inc. (301047.SZ) has a MoatMap StockRank of 70/100 based on Quality (63/100), Value (40/100), and Momentum (54/100) factor scores. The current signal is BUY. Sino Biological is a high-quality provider of recombinant proteins and contract research services, positioning it well for the CDMO pricing power cycle. However, geopolitical tensions and domestic biotech funding constraints in China present near-term headwinds that offset its strong balance sheet and high-margin product portfolio.

Key Financial Metrics

Price	$8.90
Market Cap	$1.1B
P/E (TTM)	46.71
Price/Book	1.37
Return on Equity	2.8%
Return on Invested Capital	3.4%
Debt/Equity	0.87
Gross Margin	73.2%
Operating Margin	17.5%
Revenue Growth	18.1%
Dividend Yield	8.6%
Free Cash Flow	$-787K

Sino Biological,Inc. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Sino Biological,Inc.’s (301047.SZ) StockRank?: MoatMap’s StockRank for Sino Biological,Inc. (301047.SZ) is 70/100, with a Buy signal. It is a composite of Quality (63), Value (40), and Momentum (54) factor ranks across MoatMap’s 19,000+ stock universe.
Does Sino Biological,Inc. have an economic moat?: Sino Biological,Inc. (301047.SZ) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sino Biological,Inc. a buy, hold, or sell?: MoatMap’s current signal for Sino Biological,Inc. (301047.SZ) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sino Biological,Inc. in?: Sino Biological,Inc. (301047.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).